FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Background The role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program is an open-label, phase 2 platform trial...

Full description

Bibliographic Details
Main Authors: Giuseppe Procopio, Prabhu Bhagavatheeswaran, Bernard Escudier, Chung-Han Lee, Shruti Shally Saggi, Suresh Nair, Ruth Perets, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Sebastien J. Hotte, Wilson H Miller, Heshani Desilva
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/11/e005780.full

Internet

https://jitc.bmj.com/content/10/11/e005780.full

Similar Items